Sapient enables circulating biomarker discovery at unprecedented speed and scale.

What We Enable

Discover more, develop faster, heal quicker.

Learn More

We created Sapient to drive a fundamental shift in today’s costly, slow moving, inefficient drug development process. Sapient applies an end-to-end biomarker discovery platform to provide a deeper understanding of human biology and effectively align biological targets, patients, and drug therapies.

Our Platform

Circulating Biomarker Discovery Engine

Sapient’s three-pronged platform leverages advanced mass spectrometry technologies, computational learning, and a proprietary longitudinal Human Biology Database to enable population-level discovery of biomarkers, and derive actionable insights to optimize and expedite drug development.

Drug Creation

High-throughput mass spectrometry technologies perform untargeted profiling of >11,000 circulating factors per biosample and can assay tens of thousands of samples per day.
Analytical Technologies
Data science algorithms and machine learning tools are applied to the data to reveal key biomarkers that predict disease events, drug efficacy, and adverse response.
Computational Learning
Proprietary chemical databases of >300,000 human biosamples and more than 20 million patient-years of follow-up data provide actionable insights on identified biomarkers.
Human Biology Database

Together these technologies drive significant speed and scale advantages.

Read Case Studies

Ability to assay


circulating molecules per biosample

Capacity to analyze


biosamples per day